1. Home
  2. SBMT vs ARMP Comparison

SBMT vs ARMP Comparison

Compare SBMT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silver Bow Mining Corp. Common Shares

SBMT

Silver Bow Mining Corp. Common Shares

N/A

Current Price

$6.81

Market Cap

184.0M

ML Signal

N/A

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$4.75

Market Cap

156.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBMT
ARMP
Founded
N/A
N/A
Country
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.0M
156.4M
IPO Year
2026
1996

Fundamental Metrics

Financial Performance
Metric
SBMT
ARMP
Price
$6.81
$4.75
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
77.3K
166.2K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.75
$2.36
52 Week High
$8.98
$14.98

Technical Indicators

Market Signals
Indicator
SBMT
ARMP
Relative Strength Index (RSI) 36.87 39.95
Support Level $5.90 $3.48
Resistance Level $6.60 $7.67
Average True Range (ATR) 0.38 0.56
MACD 0.06 0.13
Stochastic Oscillator 15.82 53.96

Price Performance

Historical Comparison
SBMT
ARMP

About SBMT Silver Bow Mining Corp. Common Shares

Silver Bow Mining Corp is engaged in the acquisition, exploration, and development of mineral resource properties in Butte, Montana, USA. The Company's primary business objective is to identify and evaluate prospective properties with the potential for future extraction and commercialization.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: